一线FOLFIRINOX与吉西他滨/白蛋白结合型紫杉醇化疗对晚期胰腺癌生存的影响:来自前瞻性国际多中心PURPLE胰腺癌登记研究的数据
该研究基于澳大利亚PURPLE前瞻性登记数据回顾性分析615例接受姑息化疗的晚期胰腺癌患者,比较一线FOLFIRINOX(n=73)与吉西他滨/白蛋白结合型紫杉醇(n=376)的总生存,中位OS分别为12.3个月与11.3个月(P=0.37),无显著差异;38%患者接受二线化疗,其中位OS较单纯一线治疗延长(17.4 vs 8.2个月,P<0.001)。
要点
- 一线FOLFIRINOX与吉西他滨/白蛋白结合型紫杉醇的中位OS无显著差异(12.3 vs 11.3个月,P=0.37)。
- 接受二线化疗者中位OS较仅一线治疗者延长(17.4 vs 8.2个月,P<0.001)。
- 既往FOLFIRINOX后二线治疗的中位PFS较既往吉西他滨/白蛋白结合型紫杉醇后二线治疗更长(5.2 vs 2.9个月,P=0.03)。
核心结论
- 一线FOLFIRINOX与吉西他滨/白蛋白结合型紫杉醇在晚期胰腺导管腺癌的总生存上无显著差异,尽管接受FOLFIRINOX者更年轻、体能状态更好且更可能为局限期疾病。
- FOLFIRINOX与更长的无进展生存相关。
- 在缺乏III期随机对照试验数据的情况下,临床医生可放心使用吉西他滨/白蛋白结合型紫杉醇或FOLFIRINOX作为晚期胰腺导管腺癌的一线治疗。
研究设计与样本
- 对澳大利亚PURPLE胰腺癌登记研究前瞻性收集的数据进行回顾性分析。
- 2016年至2020年间,1551例胰腺癌患者中615例接受了姑息性化疗。
- 排除早期切除无复发(n=369)、仅放疗(n=43)、仅支持治疗(n=458)及随访不足3个月(n=66)的患者。
- 接受一线吉西他滨/白蛋白结合型紫杉醇者n=376,接受FOLFIRINOX者n=73。
主要发现
- 一线吉西他滨/白蛋白结合型紫杉醇与FOLFIRINOX的中位OS分别为11.3个月与12.3个月(P=0.37)。
- 38%的患者接受了二线化疗,其二线化疗者的中位OS较仅一线治疗者更长(17.4 vs 8.2个月,P<0.001)。
- 既往FOLFIRINOX后二线治疗(n=29)与既往吉西他滨/白蛋白结合型紫杉醇后二线治疗(n=101)的中位OS分别为17.3个月与15.9个月(P=0.92),无显著差异。
- 既往FOLFIRINOX后二线治疗的中位PFS较既往吉西他滨/白蛋白结合型紫杉醇后二线治疗更长(5.2 vs 2.9个月,P=0.03)。
临床怎么用
- 作者认为,在缺乏III期随机对照试验数据的情况下,临床医生可放心使用吉西他滨/白蛋白结合型紫杉醇或FOLFIRINOX作为晚期胰腺导管腺癌的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First-line palliative chemotherapy regimens in advanced pancreatic ductal adenocarcinoma (PDAC) have not been compared in head-to-head phase III randomised controlled trials (RCT). Data on optimum first-line treatment and subsequent sequencing is lacking. OBJECTIVE: To compare overall survival (OS) between first-line treatment regimens in a real-world population to determine if an optimal therapeutic sequence is associated with survival benefit. METHODS: A retrospective analysis of prospectively collated data from the Australasian PURPLE pancreatic cancer registry was undertaken. FINDINGS: From 2016 to 2020, of 1551 pancreatic cancer patients, 615 received palliative-intent chemotherapy. Patients with early-stage resected disease without recurrence (n = 369), radiotherapy alone (n = 43), received supportive care alone (n = 458) or had less than 3 months follow-up (n = 66) were excluded. Median OS was comparable between patients receiving first-line Gemcitabine/Nab-Paclitaxel (n = 376) and those receiving FOLFIRINOX (n = 73) (11.3 versus 12.3 months, P = 0.37), with 38% proceeding to second-line chemotherapy which was associated with longer mOS compared to first-line treatment alone (17.4 versus 8.2 months, P < 0.001). With second-line treatment following prior FOLFIRINOX (n = 29) or Gemcitabine/Nab-Paclitaxel (n = 101), mOS did not differ significantly (17.3 versus 15.9 months, P = 0.92), respectively, whilst median progression-free survival was longer with prior FOLFIRINOX (5.2 versus 2.9 months, P = 0.03). CONCLUSION: There was no significant difference in overall survival between either first-line chemotherapy choice, despite patients receiving FOLFIRINOX being younger, fitter, and more likely to have localised disease. However, FOLFIRINOX was associated with delayed progression. In the absence of phase III RCT data, clinicians should be comfortable using either Gemcitabine/Nab-Paclitaxel or FOLFIRINOX as first-line therapy in advanced PDAC.
引用
- Santucci J, Tacey M, Thomson B, et al. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. Eur J Cancer. 2022. PMID: 35988408. doi:10.1016/j.ejca.2022.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。